CO6592101A2 - Metodos para tratar ulceras de pie de diabetico - Google Patents

Metodos para tratar ulceras de pie de diabetico

Info

Publication number
CO6592101A2
CO6592101A2 CO12154938A CO12154938A CO6592101A2 CO 6592101 A2 CO6592101 A2 CO 6592101A2 CO 12154938 A CO12154938 A CO 12154938A CO 12154938 A CO12154938 A CO 12154938A CO 6592101 A2 CO6592101 A2 CO 6592101A2
Authority
CO
Colombia
Prior art keywords
diabetic foot
methods
foot ulcers
treat diabetic
peptide
Prior art date
Application number
CO12154938A
Other languages
English (en)
Inventor
Kathleen E Rodgers
Gere S Dizerega
Original Assignee
Univ Southern California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45571822&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6592101(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Southern California filed Critical Univ Southern California
Publication of CO6592101A2 publication Critical patent/CO6592101A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/085Angiotensins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se encuentra dirigida a métodos para el tratamiento de úlceras de pie de diabético que comprende administrar a un paciente que sufre de úlcera de pie de diabético una cantidad de un péptido de al menos 5 aminoácidos contiguos de N1e3 A8l-7), o sal del mismo, efectiva para el tratamiento de úlcera de pie de diabético o una formulación que contiene dicho péptido.
CO12154938A 2011-02-02 2012-09-10 Metodos para tratar ulceras de pie de diabetico CO6592101A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161438780P 2011-02-02 2011-02-02

Publications (1)

Publication Number Publication Date
CO6592101A2 true CO6592101A2 (es) 2013-01-02

Family

ID=45571822

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12154938A CO6592101A2 (es) 2011-02-02 2012-09-10 Metodos para tratar ulceras de pie de diabetico

Country Status (21)

Country Link
US (3) US8207233B1 (es)
EP (1) EP2536422B8 (es)
JP (2) JP5469777B2 (es)
KR (1) KR101514414B1 (es)
CN (1) CN102858360B (es)
AU (1) AU2012212220B2 (es)
BR (1) BR112013019513A2 (es)
CA (1) CA2793515C (es)
CL (1) CL2012002560A1 (es)
CO (1) CO6592101A2 (es)
DK (1) DK2536422T3 (es)
EA (1) EA026440B1 (es)
ES (1) ES2479765T3 (es)
HK (1) HK1180213A1 (es)
MX (1) MX2012010783A (es)
PE (1) PE20130379A1 (es)
PL (1) PL2536422T3 (es)
PT (1) PT2536422E (es)
SG (1) SG183960A1 (es)
WO (1) WO2012106427A2 (es)
ZA (1) ZA201207340B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA026440B1 (ru) * 2011-02-02 2017-04-28 Университи Оф Сатерн Калифорния Способ лечения диабетической язвы стопы
US9688724B2 (en) 2012-05-14 2017-06-27 University Of Southern California Methods for limiting development of a skin wound
CN104853749A (zh) * 2012-09-17 2015-08-19 塔瑞克斯制药有限公司 血管紧张素的口服制剂
US9289500B2 (en) * 2013-02-22 2016-03-22 The Regents Of The University Of California Saccharide-peptide hydrogels
US9623084B2 (en) 2013-03-15 2017-04-18 University Of Southern California Methods for treating multiple sclerosis
DK2967049T3 (da) 2013-03-15 2020-12-07 Univ Southern California Metoder, forbindelser og sammensætninger til behandlingen af angiotensin relaterede sygdomme
WO2015138288A1 (en) * 2014-03-10 2015-09-17 Rush University Medical Center Methods of promotion of healing of diabetic wounds
WO2016108130A1 (en) * 2014-12-30 2016-07-07 Sun Pharmaceutical Industries Limited Topical pharmaceutical compositions comprising nebivolol for the treatment of diabetic wounds
US20180344680A1 (en) * 2015-12-08 2018-12-06 The Arizona Board Of Regents On Behalf Of The University Of Arizona Compositions and methods for treatment, amelioration, and prevention of diabetes-related skin ulcers
WO2021072225A1 (en) * 2019-10-09 2021-04-15 Rush University Medical Center Modulating interleukin-10 signaling to boost healing in diabetic wounds

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5015629A (en) 1989-06-26 1991-05-14 University Of Southern California Tissue repair
WO1993008825A1 (en) * 1991-11-04 1993-05-13 Zymogenetics, Inc. Pdgf gel formulation
US5955430A (en) 1993-09-24 1999-09-21 University Of Southern California Use of angiotensin II fragments and analogs thereof in tissue repair
EP0745091A4 (en) 1993-09-24 1998-05-20 Univ Southern California USE OF ANGIOTENSIN II ANALOGS IN TISSUE RECOVERY
PT730465E (pt) 1993-09-24 2002-06-28 Univ Southern California Utilizacao de angiotensina iii e de analogos desta em cicatrizacao de tecidos
US5834432A (en) 1995-06-06 1998-11-10 The University Of Southern California Use of angiotensin II Type 2 receptor agonists in tissue repair
US6110895A (en) 1996-12-16 2000-08-29 University Of Southern California Method of promoting healing in skin grafts
US6335195B1 (en) 1997-01-28 2002-01-01 Maret Corporation Method for promoting hematopoietic and mesenchymal cell proliferation and differentiation
WO1998033813A2 (en) 1997-02-04 1998-08-06 University Of Southern California Method for accelerating healing of thermal injuries
US6248587B1 (en) 1997-11-26 2001-06-19 University Of Southern Cailfornia Method for promoting mesenchymal stem and lineage-specific cell proliferation
CA2315266C (en) 1997-12-12 2004-08-10 University Of Southern California Wound healing compositions
AU2593599A (en) 1998-02-09 1999-08-23 University Of Southern California Method of promoting keratinocyte proliferation
US6455500B1 (en) 1998-03-10 2002-09-24 University Of Southern California Radiation therapy methods
US7173011B2 (en) 2000-11-20 2007-02-06 University Of Southern California Radiation therapy methods
WO1999046285A2 (en) 1998-03-11 1999-09-16 University Of Southern California Method of promoting production of living tissue equivalents
US6762167B1 (en) 1998-05-11 2004-07-13 University Of Southern California Methods for treating a patient undergoing chemotherapy
AU759285B2 (en) 1998-05-11 2003-04-10 University Of Southern California Methods to increase white blood cell survival after chemotherapy
US6916783B2 (en) 1998-07-13 2005-07-12 University Of Southern California Methods for accelerating bone and cartilage growth and repair
EP1094829B8 (en) 1998-07-13 2004-09-22 University Of Southern California Methods for accelerating bone and cartilage growth and repair
EP1105149A1 (en) 1998-08-13 2001-06-13 University Of Southern California Methods to increase blood flow to ischemic tissue
US6730775B1 (en) 1999-03-23 2004-05-04 University Of Southern California Methods for limiting scar and adhesion formation
US7338938B2 (en) 1999-05-10 2008-03-04 University Of Southern California Methods for treating a patient undergoing chemotherapy
AU1792901A (en) 1999-12-16 2001-06-25 University Of Southern California Methods for treating and preventing diabetic complications
US6821953B1 (en) 1999-12-16 2004-11-23 University Of Southern California Methods for treating and preventing damage to mucosal tissue
EP1292610A1 (en) * 2000-06-19 2003-03-19 University Of Southern California Methods for treating and preventing alopecia
US20060058238A1 (en) * 2004-09-15 2006-03-16 Lee Laurent-Applegate Fetal skin cell protein compositions for the treatment of skin conditions, disorders or diseases and methods of making and using the same
EP2245061A2 (en) * 2007-12-11 2010-11-03 Coda Therapeutics, Inc. Impaired wound healing compositions and treatments
US20090227507A1 (en) 2008-03-10 2009-09-10 University Of Southern California Angiotensin (1-7) Dosage Forms and Uses Thereof
SG184247A1 (en) 2010-03-26 2012-10-30 Univ Southern California Methods for treating combined radiation and thermal injury
JP2013533315A (ja) 2010-08-10 2013-08-22 ユニバーシティー オブ サザン カリフォルニア 細胞移植における、及びノロウイルス感染症を防止/治療する薬剤としてのアンジオテンシンii(1−7)の使用
EA026440B1 (ru) * 2011-02-02 2017-04-28 Университи Оф Сатерн Калифорния Способ лечения диабетической язвы стопы

Also Published As

Publication number Publication date
US8207233B1 (en) 2012-06-26
US8207234B1 (en) 2012-06-26
KR101514414B1 (ko) 2015-05-04
CN102858360B (zh) 2017-07-25
JP5469777B2 (ja) 2014-04-16
CN102858360A (zh) 2013-01-02
EA026440B1 (ru) 2017-04-28
PT2536422E (pt) 2014-07-18
ZA201207340B (en) 2013-02-27
SG183960A1 (en) 2012-10-30
MX2012010783A (es) 2012-11-23
WO2012106427A2 (en) 2012-08-09
EP2536422A2 (en) 2012-12-26
PL2536422T3 (pl) 2014-09-30
ES2479765T3 (es) 2014-07-24
US20120329729A1 (en) 2012-12-27
EP2536422B1 (en) 2014-04-30
EP2536422B8 (en) 2023-06-21
CL2012002560A1 (es) 2013-03-22
EA201201296A1 (ru) 2013-02-28
CA2793515A1 (en) 2012-08-09
HK1180213A1 (en) 2013-10-18
DK2536422T3 (da) 2014-07-28
WO2012106427A3 (en) 2012-09-20
KR20120137365A (ko) 2012-12-20
JP2013523781A (ja) 2013-06-17
PE20130379A1 (es) 2013-04-13
US8536231B2 (en) 2013-09-17
CA2793515C (en) 2015-05-12
AU2012212220B2 (en) 2013-04-04
JP2014080425A (ja) 2014-05-08
AU2012212220A1 (en) 2012-10-18
BR112013019513A2 (pt) 2019-06-11

Similar Documents

Publication Publication Date Title
CO6592101A2 (es) Metodos para tratar ulceras de pie de diabetico
CL2019001079A1 (es) Métodos para usar indazol-3-carboxamidas y su uso como inhibidores de la vía de señalización de wnt/b-catenina.
EA201692506A2 (ru) Ингибиторы репликации вирусов гриппа
DOP2015000240A (es) 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante
MX2022013172A (es) Uso de un inhibidor de pcsk9 para tratar la hiperlipidemia.
CL2015001241A1 (es) Uso de interleucina 2 (il-2) para tratar trastornos inflamatorios o relacionados con la autoinmunidad (div. sol. n° 2608-13)
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
CO6382125A2 (es) Inhibidores de proteína quinasa
BR112014009418A2 (pt) macrociclos peptidomiméticos
EA201991014A1 (ru) Лечение диабета
CO6430430A2 (es) Compuestos para la reduccion de produccionn de beta-amiloide
EA201391581A1 (ru) Способы лечения болезни альцгеймера, болезни хантингтона, аутизма и других расстройств
EA201490378A1 (ru) ЛЕЧЕНИЕ РАССЕЯННОГО СКЛЕРОЗА С ИСПОЛЬЗОВАНИЕМ КОМБИНАЦИИ ЛАХИНИМОДА И ИНТЕРФЕРОНА-β
BR112017007144A2 (pt) ácido valproico ou um sal farmaceuticamente aceitável do mesmo, composto, composição farmacêutica, e, composto ou composição para uso, uso, método ou composição.
AR101740A1 (es) Terapia de combinación y composiciones
MX356728B (es) Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2.
CO6710913A2 (es) Uso de ácido lipasa lisosomal para tratar la deficiencia de ácido lipasa lisosomal en pacientes
BR112012033738A2 (pt) método para o tratamento de transtorno bipolar
BR112013020586A2 (pt) Uso de células derivadas de tecido do cordão umbilical
BR112014011223A2 (pt) método de tratar uma doença proliferativa
UY33568A (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes.
UY33453A (es) Método para el tratamiento de la hipertensión pulmonar mediante el uso de ranozalina
CO7121334A2 (es) Formulaciones vesiculares
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
BR112015012497A2 (pt) combinações farmacêuticas